Paulson et al. Serial No. 08/063,181

Page 7

Jul B3

- 120. The method of claim 95, wherein the pharmaceutically acceptable carrier comprises sodium ions.
- 121. The method of claim 95, wherein the pharmaceutically acceptable carrier comprises sodium acetate.
- 122. The method of claim 95, wherein the composition is administered parenterally.
- 123. The method of claim 122, wherein the therapeutically effective dose is between about 0.15 mg/kg to about 29 mg/kg.

B4 124. The method of claim 95, wherein the intercellular adhesion is associated with an inflammatory condition.

125. The method of claim 124, wherein the inflammatory condition is acute respiratory distress syndrome.

126. The method of claim 95, wherein the intercellular adhesion is associated with reperfusion injury.

127. The method of claim 126, the reperfusion injury is myocardial ischemia-reperfusion injury. —

REMARKS

In response to a telephonic restriction requirement from Examiner Saunders

Applicants' have elected with traverse to prosecute the claims of group IV, claims 67-80. At

 \mathcal{A}'

Paulson et al. Serial No. 08/063,181 Page 8

that time Applicants' attorney informed Examiner Saunders that this preliminary would be filed.

Support for the above claims is found primarily in the claims as originally filed. Specific support for formula II of claim 99 is found on page 13, lines 3 to 10. Specific support for claim 114, and the claims which depend from it, is found in the structures presented in Figure 12B. Specific support for claim 121 at page 47, lines 36-37. Specific support for claim 123 is found at page 49, lines 35-39.

If a telephone conference would expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (415) 543-9600.

Respectfully submitted,

By Kevin L. Bastian

Reg. No. 34,774

Townsend and Townsend Khourie and Crew Steuart Street Tower, 20th Floor One Market Plaza San Francisco, California 94105 Telephone: (415) 543-9600